[go: up one dir, main page]

AR046083A1 - Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos - Google Patents

Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos

Info

Publication number
AR046083A1
AR046083A1 ARP040103354A ARP040103354A AR046083A1 AR 046083 A1 AR046083 A1 AR 046083A1 AR P040103354 A ARP040103354 A AR P040103354A AR P040103354 A ARP040103354 A AR P040103354A AR 046083 A1 AR046083 A1 AR 046083A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
optionally further
further substituted
independently selected
Prior art date
Application number
ARP040103354A
Other languages
English (en)
Inventor
Peter Hansen
Karolina Lawitz
Hans Lonn
Antonios Nikitidis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29212489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046083A1 publication Critical patent/AR046083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), en donde: Y representa CR3 o N; R1 representa H o (C1-6) alquilo; R2 representa: i) CN, NO2, OH, OSO2R47, O-(C2-6) alcanoilo, CO2R47, CHO o (C2-6) alcanoilo; o ii) (C1-6) alcoxi opcionalmente sustituido por OH, (C1-6) alcoxi, CN, NR54R55, CONR54R55, OCOR47 o uno o más átomos de F; o iii) (C3-6) cicloalquilo saturado o parcialmente insaturado opcionalmente sustituido adicionalmente por (C1-6) alquilo; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S(O)m y NR62 opcionalmente sustituido adicionalmente por (C1-6) alquilo; o v) CONR48R49, CONR50NR48R49, C(=NOR52)R53, C(=NH)NHOR52 o NR48R49; o (C2-6) alquenilo o (C2-6) alquinilo; estando dicho grupo alquenilo o alquinilo opcionalmente sustituido adicionalmente por (C1-6) alcoxi o fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo fenilo o heteroaromático opcionalmente sustituido adicionalmente por halógeno, CN, (C1-6) alquilo o (C1-6) alcoxi; o vii) (C1-6) alquilo sustituido por uno o más átomos de F; o viii) (C1-6) alquilo sustituido por uno o más grupos seleccionados entre halógeno, OH, oxo, azido, R48R49, (C1-6) alcoxi y (C1-6) alcoxi sustituido por uno o más átomos de F; o ix) (C1-6) alquilo sustituido por fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo fenilo o heteroaromático opcionalmente sustituido adicionalmente por halógeno, CN, (C1-6) alquilo o (C1-6) alcoxi; R48 y R49 en forma independiente representan H, OH, (C1-6) alcoxi, (C3-6) cicloalquilo, CHO, (C2-6) alcanoilo, CO2R50, C(X)NR63R64 o (C1-6) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por OH, (C1-4) alcoxi, (C3-6) cicloalquilo, CN, o fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho alcanoilo opcionalmente sustituido adicionalmente por CN; X representa O o S; o el grupo R48R49 en conjunto representa un anillo azacíclico saturado o parcialmente insaturado de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR56; estando dicho anillo azacíclico opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados entre OR57 y (C1-4) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por OR57; R3 representa H o F; G1 representa fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; R5 representa H, halógeno, (C1-6) alquilo, CN, (C1-6) alcoxi, NO2, NR14R15, (C1- 3) alquilo sustituido por uno o más átomos de F o (C1-3) alcoxi sustituido por uno o más átomos de F; R14 y R15 en forma independiente representan H o (C1-3) alquilo; estando dicho alquilo opcionalmente sustituido adicionalmente por uno o más átomos de F; n representan un entero 1, 2 ó 3 y cuando n representa 2 ó 3, cada grupo R5 se selecciona en forma independiente; R4 representa H o (C1-6) alquilo, estando dicho alquilo opcionalmente sustituido adicionalmente por OH o (C1-6) alcoxi; o R4 y L están unidos de forma tal que el grupo -R4L representan un anillo azacíclico de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR16; estando dicho anillo opcionalmente sustituido adicionalmente por (C1- 6) alquilo o NR60R61; estando dicho alquilo opcionalmente sustituido adicionalmente por OH; L representa un enlace, O, NR29 o (C1-6) alquilo; donde dicho alquilo incorpora opcionalmente un heteroátomo seleccionado entre O, S y NR16; y estando dicho alquilo opcionalmente sustituido adicionalmente por OH o OMe; G2 representa un sistema de anillo monocíclico seleccionado entre: i) fenilo o fenoxi; ii) un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; iii) un cicloalquilo (C3-6) saturado o parcialmente insaturado; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; o G2 representa un sistema de anillo bicíclico en donde cada uno de los dos anillos se selecciona en forma independiente entre: i) fenilo; ii) un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; iii) un cicloalquilo (C3-6) saturado o parcialmente insaturado; o iv) un anillo heterocíclico (C4-7) saturado o parcialmente insaturado que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; y los dos anillos o bien están fusionados, o están unidos directamente juntos o están separados por un grupo ligante seleccionado entre O, S(O)q o CH2; estando dicho sistema de anillo monocíclico o bicíclico opcionalmente sustituido adicionalmente por entre uno y tres sustituyentes seleccionados en forma independiente entre CN, OH, (C1-6) alquilo, (C1-6) alcoxi, halógeno, NR18R19, NO2, OSO2R38, CO2R20, C(=NH)NH2, C(O)NR21R22, C(S)NR23R24, SC(=NH)NH2, NR31C(=NH)NH2, S(O)SR25, SO2NR26R27, (C1-3) alcoxi sustituido por uno o más átomos de F y (C1-3) alquilo sustituido por SO2R39 o por uno o más átomos de F; o cuando L no representa un enlace, G2 también puede representar H; en cada caso m, p, q, s y t en forma independiente representa un entero 0, 1 ó 2; R18 yR19 en forma independiente representan H, (C1-6) alquilo, formilo, (C2-6) alcanoilo, S(O)tR32 o SO2NR33R34; estando dicho grupo alquilo opcionalmente sustituido adicionalmente por halógeno, CN, (C1-4) alcoxi o COR41R42; R25 representa H, (C1-6) alquilo o (C3-6) cicloalquilo; estando dicho grupo alquilo opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados en forma independiente entre OH, CN, CONR35R36, CO2R37, OCOR40, (C3-6) cicloalquilo, un anillo heterocíclico saturado de C4-7 que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y R43 y fenilo o un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; estando dicho anillo aromático opcionalmente sustituido adicionalmente por uno o más sustituyentes seleccionados en forma independiente entre halógeno, CN, (C1-4) alquilo, (C1-4) alcoxi, OH, CONR44R45, CO2R46, S(O)SR65 y NHCOCH3; R32 representa H, (C1-6) alquilo o (C3- 6) cicloalquilo; R16, R17, R20, R21, R22, R23, R24, R26, R27, R29, R31, R33, R34, R35, R36, R37, R38, 39, R40, R41, R42, R43, R44, R45, R46, R47, R50, R52, R53, R54, R55, R56, R57, R60, R61, R62, R63, R64 y R65 en forma independiente representan H o (C1-6) alquilo; y sus sales aceptables para uso farmacéutico.
ARP040103354A 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos AR046083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302487A SE0302487D0 (sv) 2003-09-18 2003-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
AR046083A1 true AR046083A1 (es) 2005-11-23

Family

ID=29212489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103354A AR046083A1 (es) 2003-09-18 2004-09-17 Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos

Country Status (25)

Country Link
US (1) US20070043036A1 (es)
EP (1) EP1663974B1 (es)
JP (1) JP2007505902A (es)
KR (1) KR20060096995A (es)
CN (1) CN100439339C (es)
AR (1) AR046083A1 (es)
AT (1) ATE420861T1 (es)
AU (1) AU2004272485B2 (es)
BR (1) BRPI0414570A (es)
CA (1) CA2538410A1 (es)
CO (1) CO5670357A2 (es)
DE (1) DE602004019110D1 (es)
ES (1) ES2319300T3 (es)
IL (1) IL173986A0 (es)
IS (1) IS8394A (es)
MX (1) MXPA06002723A (es)
NO (1) NO20061700L (es)
RU (1) RU2348617C2 (es)
SA (1) SA04250300B1 (es)
SE (1) SE0302487D0 (es)
TW (1) TW200526579A (es)
UA (1) UA84878C2 (es)
UY (1) UY28513A1 (es)
WO (1) WO2005026124A1 (es)
ZA (1) ZA200602262B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
PT1928454E (pt) * 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP2009509979A (ja) * 2005-09-29 2009-03-12 ユニバーシティ オブ アルバータ グランザイムｂ阻害のための組成物および方法
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
PT2089364E (pt) 2006-11-08 2013-08-26 Bristol Myers Squibb Co Compostos de piridinona
CL2008003301A1 (es) 2007-11-06 2009-10-16 Astrazeneca Ab Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras.
CN101970405A (zh) 2007-12-14 2011-02-09 普尔马金医疗(哮喘)有限公司 吲哚及其治疗用途
AU2009206440B2 (en) 2008-01-23 2013-08-15 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
JP2012517992A (ja) 2009-02-17 2012-08-09 チェシ ファーマスーティシ エス．ピー．エイ． Ｐ３８ｍａｐキナーゼインヒビターとしてのトリアゾロピリジン誘導体
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
RU2012116877A (ru) * 2009-10-02 2013-11-10 Астразенека Аб Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
IN2012DN05081A (es) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
SG10201604656YA (en) 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
PT2788349T (pt) 2011-12-09 2017-02-02 Chiesi Farm Spa Inibidores de cinase
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
BR112015029970A2 (pt) 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
AR105875A1 (es) 2015-09-02 2017-11-15 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (Nº 2) LTD Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
EP3394060A1 (en) 2015-12-23 2018-10-31 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
KR20190045302A (ko) 2016-09-06 2019-05-02 에프. 호프만-라 로슈 아게 8-(아제티딘-1-일)-[1,2,4]트라이아졸로[1,5-a]피리딘일 화합물 및 이의 조성물 및 사용 방법
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
US20180334465A1 (en) 2017-05-22 2018-11-22 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
CR20190520A (es) 2017-05-22 2020-01-21 Hoffmann La Roche Composiciones y compuestos terapéuticos y métodos para utilizarlos
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
PH12021552998A1 (en) 2019-06-18 2023-08-14 Hoffmann La Roche Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
MX2022012942A (es) 2020-04-16 2023-01-11 Mereo Biopharma 4 Ltd Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina.
IL312002A (en) 2021-10-20 2024-06-01 Mereo Biopharma 4 Ltd Neutrophil elastase inhibitors for use in the treatment of fibrosis
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
FR2687674B1 (fr) * 1992-02-07 1995-05-19 Roussel Uclaf Nouveaux derives de la pyridone, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
EP0729464A1 (en) * 1993-11-19 1996-09-04 PARKE, DAVIS & COMPANY 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
RU2067579C1 (ru) * 1994-10-07 1996-10-10 Пермский фармацевтический институт 3-(2'-нафтоилметилен)-пиперазинон-2 и 1-n-фенил-3-фенацилиденпиперазинон-2, проявляющие противовоспалительную активность
KR100828982B1 (ko) * 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1458682B1 (en) * 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
GB2383326A (en) * 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
IS8394A (is) 2006-03-31
TW200526579A (en) 2005-08-16
IL173986A0 (en) 2006-07-05
EP1663974A1 (en) 2006-06-07
MXPA06002723A (es) 2006-06-06
CN1856467A (zh) 2006-11-01
JP2007505902A (ja) 2007-03-15
HK1089167A1 (en) 2006-11-24
EP1663974B1 (en) 2009-01-14
DE602004019110D1 (de) 2009-03-05
SE0302487D0 (sv) 2003-09-18
ATE420861T1 (de) 2009-01-15
CN100439339C (zh) 2008-12-03
CO5670357A2 (es) 2006-08-31
UY28513A1 (es) 2005-04-29
UA84878C2 (ru) 2008-12-10
AU2004272485B2 (en) 2008-03-13
ES2319300T3 (es) 2009-05-06
RU2006112427A (ru) 2007-11-10
NO20061700L (no) 2006-04-18
BRPI0414570A (pt) 2006-11-07
WO2005026124A1 (en) 2005-03-24
US20070043036A1 (en) 2007-02-22
ZA200602262B (en) 2007-07-25
CA2538410A1 (en) 2005-03-24
SA04250300B1 (ar) 2008-09-07
KR20060096995A (ko) 2006-09-13
RU2348617C2 (ru) 2009-03-10
AU2004272485A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
AR046083A1 (es) Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
AR042024A1 (es) Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona
AR067327A1 (es) Derivados de piperidina / piperazina
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
AR069543A1 (es) Derivados bis-(sulfonilamino), composiciones farmaceuticas que los contienen y su uso en terapia.
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CO5700774A2 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR060874A1 (es) Compuestos derivados de 2-piperazinona
SE0303180D0 (sv) Novel compounds
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
SE0302232D0 (sv) Novel Compounds
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR033594A1 (es) Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
CO6241115A2 (es) Compuestos y composiciones como inhibidores de protein quinasas
SE0201635D0 (sv) Novel compounds
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister

Legal Events

Date Code Title Description
FA Abandonment or withdrawal